Louis Moore Bacon's TRDA Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 105,000 shares of Entrada Therapeutics, Inc. (TRDA) worth $1.33 M, representing 0.03% of the portfolio. First purchased in 2021-Q4, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Louis Moore Bacon has maintained a strategic position in TRDA, demonstrating sustained confidence in this investment.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Entrada Therapeutics (TRDA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Entrada Therapeutics (TRDA) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2021 | +105,000 | New Buy | 105,000 | $17.12 |
Louis Moore Bacon's Entrada Therapeutics Investment FAQs
Louis Moore Bacon first purchased Entrada Therapeutics, Inc. (TRDA) in Q4 2021, acquiring 105,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Entrada Therapeutics, Inc. (TRDA) for 18 quarters since Q4 2021.
Louis Moore Bacon's largest addition to Entrada Therapeutics, Inc. (TRDA) was in Q4 2021, adding 105,000 shares worth $1.8 M.
According to the latest 13F filing for Q1 2026, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 105,000 shares of Entrada Therapeutics, Inc. (TRDA), valued at approximately $1.33 M.
As of the Q1 2026 filing, Entrada Therapeutics, Inc. (TRDA) represents approximately 0.03% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in Entrada Therapeutics, Inc. (TRDA) was 105,000 shares, as reported at the end of Q4 2021.